Dystrophin is a tumor suppressor in human cancers with myogenic programs. - Wikidata - wikimedia - TriplyDB

Dystrophin is a tumor suppressor in human cancers with myogenic programs.

Dystrophin is a tumor suppressor in human cancers with myogenic programs.

http://www.wikidata.org/entity/Q34479070

about

Advances in the Molecular Analysis of Soft Tissue Tumors and Clinical Implications Animal models of Duchenne muscular dystrophy: from basic mechanisms to gene therapy Atypical Lipomatous Tumor/Well-Differentiated Liposarcoma Developed in a Patient with Progressive Muscular Dystrophy: A Case Report and Review of the Literature Current state of pediatric sarcoma biology and opportunities for future discovery: A report from the sarcoma translational research workshop.MURC/cavin-4 Is Co-Expressed with Caveolin-3 in Rhabdomyosarcoma Tumors and Its Silencing Prevents Myogenic Differentiation in the Human Embryonal RD Cell Line.Targeting Disease Persistence in Gastrointestinal Stromal Tumors Dystrophin deficiency reduces atherosclerotic plaque development in ApoE-null mice Probing for a deeper understanding of rhabdomyosarcoma: insights from complementary model systems.Dp412e: a novel human embryonic dystrophin isoform induced by BMP4 in early differentiated cells.Molecular characterization of metastatic exon 11 mutant gastrointestinal stromal tumors (GIST) beyond KIT/PDGFRα genotype evaluated by next generation sequencing (NGS)Dystrophin expression in muscle stem cells regulates their polarity and asymmetric division.Satellite Cells in Muscular Dystrophy - Lost in Polarity.Decreased Dp71 expression is associated with gastric adenocarcinoma prognosis.MAX inactivation is an early event in GIST development that regulates p16 and cell proliferation.Non-myogenic tumors display altered expression of dystrophin (DMD) and a high frequency of genetic alterations.Alternative splicing of DNA damage response genes and gastrointestinal cancers.Pathoproteomic profiling of the skeletal muscle matrisome in dystrophinopathy associated myofibrosis.Identification of Sets of Cytoskeletal Related and Adhesion-related Coding Region Mutations in the TCGA Melanoma Dataset that Correlate with a Negative Outcome.Neuronal SH-SY5Y cells use the C-dystrophin promoter coupled with exon 78 skipping and display multiple patterns of alternative splicing including two intronic insertion events.Cavin-1 and Caveolin-1 are both required to support cell proliferation, migration and anchorage-independent cell growth in rhabdomyosarcoma.ABC of multifaceted dystrophin glycoprotein complex (DGC).Novel Insights into the Treatment of Imatinib-Resistant Gastrointestinal Stromal Tumors.Expression deregulation of mir31 and CXCL12 in two types of oral precancers and cancer: importance in progression of precancer and cancer Dystrophin: The dead calm of a dogma.Smoking correlates with increased cytoskeletal protein-related coding region mutations in the lung and head and neck datasets of the cancer genome atlas.Protected cytoskeletal-related proteins: Towards a resolution of contradictions regarding the role of the cytoskeleton in cancer.Genetic progression in gastrointestinal stromal tumors: mechanisms and molecular interventions.Prognostic significance of decreased expression of six large common fragile site genes in oropharyngeal squamous cell carcinomas.Dystrophin deregulation is associated with tumor progression in KIT/PDGFRA mutant gastrointestinal stromal tumors DMD transcripts in CRL-2061 rhabdomyosarcoma cells show high levels of intron retention by intron-specific PCR amplification.Cell cycle and dystrophin dysregulation in GIST.Pan-cancer analysis of homozygous deletions in primary tumours uncovers rare tumour suppressors.The human, F-actin-based cytoskeleton as a mutagen sensor.Multiple Species Comparison of Cardiac Troponin T and Dystrophin: Unravelling the DNA behind Dilated Cardiomyopathy.What is New in Gastrointestinal Stromal Tumor?Integrated Molecular Characterization of Gastrointestinal Stromal Tumors (GIST) Harboring the Rare D842V Mutation in PDGFRA Gene.Targeting muscle stem cell intrinsic defects to treat Duchenne muscular dystrophy.Dissecting the Mutational Landscape of Cutaneous Melanoma: An Omic Analysis Based on Patients from Greece.Tissue- and case-specific retention of intron 40 in mature dystrophin mRNA Pannexin 1 inhibits rhabdomyosarcoma progression through a mechanism independent of its canonical channel function

P2860

Q27021848-54FC9CF8-D221-44B5-B230-905E019410ED Q28084979-38AD3E1D-0DE9-4037-9D54-1D605DEAFB78 Q33786885-96EAC7CF-9C69-4846-8A8F-D5ABDF9C91C5 Q33872384-CCC9D4DA-F328-4558-A452-9943F4F38B21 Q35667137-5262226D-A378-434A-AC3F-C9D982BC924B Q35777530-1B2C68CF-4C37-4CAB-80F7-EE8C26BFF5F4 Q36034211-4BDC764B-2B0B-4B0A-8BD7-D41E3E6993C3 Q36142754-225F9CC0-42A7-4E28-BE1B-05E184537CA8 Q36278519-CEA26F6C-270A-440C-BF1C-9B6A99B47C78 Q36561734-D3745DA7-5E46-417A-8AC0-0D6C09FB4C67 Q36822975-D7085517-5BAA-40AE-AF75-1F68823D5CA1 Q36948468-8B515324-3D46-4D91-B548-EB5741DECD10 Q37619815-CA46E822-47F4-4BAB-9CA3-119FCD800ADE Q37692151-87EA3119-CB54-4575-87CC-B7CAE8735D0E Q37702112-0E2BE76B-2C1C-4913-B6D4-B76292FD7C6E Q38291477-D610DAB5-9A88-4549-A5A1-A797E4DBB1B9 Q38563300-E9945F11-636D-4E92-BE67-F4E7B0C79AFA Q38703661-4B8F79BE-DD0D-4226-A8E2-51ECA4CD8FA5 Q38855628-CF2701BD-299C-4846-8A64-6A44EC20DC89 Q38893243-C5E96E29-CEF5-428E-B9D0-E6B36CB4F55A Q39278570-B2BC0A71-D77C-46D1-90D9-70C5834BE197 Q39288497-43468CD6-9905-4F8E-84D9-530255502248 Q39420865-E3F00FBB-7C82-4078-9B6C-2E3F739F80F3 Q40401861-0D59554E-C3E8-4BDA-B784-6744596A8824 Q40650418-AE6B69AD-648D-470F-A9AD-4C41F97BE1CB Q41116449-B7F4D9AC-02A7-42D7-889D-11375A9210A0 Q41694334-7A7AF7C6-E483-4F92-96ED-580047A594E8 Q41852350-0BFF01BC-A84E-4112-AFD7-9264FD8CEB94 Q41983985-6651D606-DE68-4676-93E2-442C3503080A Q42247648-56C88C2D-5154-416D-8245-ECDABBD9D92F Q43209031-458A454A-CA46-4547-B0BF-8544B12DB939 Q45988269-7E525307-CA5C-464D-9030-EACDF970D336 Q47162190-D9F0E44D-83A1-43AE-B5E6-2E4C75DC4983 Q48172088-4455903E-2E6E-4EE6-8CA9-476A630F9E38 Q50575961-A7D7AFD6-78E2-4538-96A1-6912C963094D Q52728496-532A267A-FD79-45EC-BADD-8F069623C188 Q55063443-844EF058-EE6D-4176-AC56-9239012A2B68 Q55397223-A95B7FDE-9271-4EBD-A472-E3C6AB76F17C Q56697960-A638E364-1157-4F17-8B3C-0401DC89697C Q59134675-6F14C4C3-B1C2-4143-8B46-B9AC22D086D7

P2860

Dystrophin is a tumor suppressor in human cancers with myogenic programs.

http://www.wikidata.org/entity/Q34479070

description

2014 nî lūn-bûn

@nan

2014 թուականի Մայիսին հրատարակուած գիտական յօդուած

@hyw

2014 թվականի մայիսին հրատարակված գիտական հոդված

@hy

2014年の論文

@ja

2014年論文

@yue

2014年論文

@zh-hant

2014年論文

@zh-hk

2014年論文

@zh-mo

2014年論文

@zh-tw

2014年论文

@wuu

name

Dystrophin is a tumor suppressor in human cancers with myogenic programs.

@ast

Dystrophin is a tumor suppressor in human cancers with myogenic programs.

@en

Dystrophin is a tumor suppressor in human cancers with myogenic programs.

@nl

type

label

Dystrophin is a tumor suppressor in human cancers with myogenic programs.

@ast

Dystrophin is a tumor suppressor in human cancers with myogenic programs.

@en

Dystrophin is a tumor suppressor in human cancers with myogenic programs.

@nl

prefLabel

Dystrophin is a tumor suppressor in human cancers with myogenic programs.

@ast

Dystrophin is a tumor suppressor in human cancers with myogenic programs.

@en

Dystrophin is a tumor suppressor in human cancers with myogenic programs.

@nl

P1433

Q34479070-812ED2BD-4D34-4AC7-9D33-FCCE2A5974A0

P1476

Q34479070-A4B01B20-6086-439C-B4F6-3C6F02D3319A

P2093

Q34479070-07695B95-B8E7-41EF-B25C-AE1DD43C0B85

Q34479070-0C499258-AAF0-4E5C-A00F-E842879513A0

Q34479070-10185DA6-AB0F-4C45-9A2A-0280AA106C43

Q34479070-1742A6B1-1806-4B87-87E5-A9122E1644D9

Q34479070-5F214BD4-EA0B-4E5E-B5B8-7CD026110856

Q34479070-6140FD1E-046A-42A0-88A1-77BC8CCAF54A

Q34479070-85B47D52-2756-4956-8037-E2DBA3E4DFF9

Q34479070-87947E18-AF8D-4B8A-BDC0-025178C35E13

Q34479070-881003F5-6AC7-4BC3-8093-CD5FD7B30E8E

Q34479070-9C3970A2-FCFE-4462-9C13-80FFFF0E6CAF

P2860

Q34479070-044F5F5A-E6D2-4696-8613-8AFF1670F87D

Q34479070-0678898B-0EE7-4888-8A8B-C6E2EF278112

Q34479070-0F603B03-ABA5-4715-BF87-306FE4B19183

Q34479070-19284640-73D6-4E01-8E12-A346DD324041

Q34479070-1AD46604-2A86-4CD1-A9EE-8BCD9CD1FA85

Q34479070-213D2551-00FE-4DFA-9234-9A11648F70A5

Q34479070-2622145E-3081-4365-AEAE-308388D6458A

Q34479070-303B3DEC-C50C-4111-8B94-F8A60E0B2FC2

Q34479070-318E8815-5FB7-49A4-8888-5E4E0788F9E5

Q34479070-342DDB68-0052-42A7-B231-B8C0FAB3218C

P2888

Q34479070-711B2DAE-E63C-44F6-A671-05DBE5BD00CD

P304

Q34479070-4A4225E6-C8CC-41FE-AEBF-CA6546F86F5B

P31

Q34479070-3B72C745-D73D-41B2-88AA-78A7AC85C2EC

P356

Q34479070-283DF258-AFE7-4DFD-9D43-D385A3BA26E3

P407

Q34479070-DE24F363-67B0-42C1-BA80-BF0ED956D465

P433

Q34479070-9F4A4968-F79A-44C1-868F-8B62030A2439

P478

Q34479070-6EA471BD-4217-4F8E-95BE-C7D6EC043F6D

P50

Q34479070-20DCEC97-85E1-4847-9566-716D3760B093

Q34479070-472E75A7-7BA0-43E6-87DB-62B96ADD2135

Q34479070-7DC14D27-A49D-4F5F-8E2E-32A67E7A73EA

P577

Q34479070-E01561E6-61A0-49CC-AFEA-9ADD0E7DE3AE

P5875

Q34479070-4EF67F15-EADD-4FCB-9835-978E64840E4D

P698

Q34479070-11D85C0B-555E-4C7A-A294-DB20F33A52E9

P932

Q34479070-88F54C5A-A14C-406E-8A23-1A313E9C5982

P356

P1433

Nature Genetics

P1476

Dystrophin is a tumor suppressor in human cancers with myogenic programs.

@en

P2093

Adrian Marino-Enriquez

http://www.w3.org/2001/XMLSchema#string

Benjamin S Fletcher

http://www.w3.org/2001/XMLSchema#string

Chandrajit P Raut

http://www.w3.org/2001/XMLSchema#string

Christopher D M Fletcher

http://www.w3.org/2001/XMLSchema#string

Cristina R Antonescu

http://www.w3.org/2001/XMLSchema#string

Edward A Fox

http://www.w3.org/2001/XMLSchema#string

George D Demetri

http://www.w3.org/2001/XMLSchema#string

Grant Eilers

http://www.w3.org/2001/XMLSchema#string

Joern Henze

http://www.w3.org/2001/XMLSchema#string

Jonathan A Fletcher

http://www.w3.org/2001/XMLSchema#string

P2860

Hallmarks of Cancer: The Next Generation

Dystrophin Dp71: the smallest but multifunctional product of the Duchenne muscular dystrophy gene

The 'ins' and 'outs' of podosomes and invadopodia: characteristics, formation and function

Exon skipping and dystrophin restoration in patients with Duchenne muscular dystrophy after systemic phosphorodiamidate morpholino oligomer treatment: an open-label, phase 2, dose-escalation study

Antibody therapy targeting the CD47 protein is effective in a model of aggressive metastatic leiomyosarcoma

The Xist RNA A-repeat comprises a novel AUCG tetraloop fold and a platform for multimerization

Gain-of-function mutations of c-kit in human gastrointestinal stromal tumors

Digital karyotyping reveals frequent inactivation of the dystrophin/DMD gene in malignant melanoma

Daily treatment with SMTC1100, a novel small molecule utrophin upregulator, dramatically reduces the dystrophic symptoms in the mdx mouse

p53 modulation as a therapeutic strategy in gastrointestinal stromal tumors

P2888

P304

601-606

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1038/NG.2974

http://www.w3.org/2001/XMLSchema#string

P407

P433

6

http://www.w3.org/2001/XMLSchema#string

P478

46

http://www.w3.org/2001/XMLSchema#string

P50

Matt van de Rijn

P577

2014-05-04T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

262052118

http://www.w3.org/2001/XMLSchema#string

P698

24793134

http://www.w3.org/2001/XMLSchema#string

P932

4225780

http://www.w3.org/2001/XMLSchema#string